查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1708240

口服抗糖尿病药物市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

Oral Antidiabetic Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球口服抗糖尿病药物市场规模达 459 亿美元，预计 2025 年至 2034 年期间的复合年增长率为 3.9%。该市场的成长主要得益于全球糖尿病盛行率的上升，尤其是第 2 型糖尿病 (T2DM)。被诊断出患有 2 型糖尿病的人数不断增加，尤其是在发展中国家，这可以归因于普遍存在的久坐生活方式和不良的饮食习惯。肥胖是导致胰岛素阻抗的主要原因，进一步加剧了对调节血糖水平的口服药物的需求。钠葡萄糖转运蛋白 2 (SGLT-2) 抑制剂和二肽基肽酶 4 (DPP-4) 抑制剂等药物越来越受欢迎。这些药物除了能有效控制血糖水平外，还能起到管理体重的额外作用，为患者的病情提供全面的解决方案。

口服抗糖尿病药物市场 - IMG1

此市场按药物类别细分为双胍类、SGLT-2 抑制剂、DPP-4 抑制剂、磺酰脲类、噻唑烷二酮类、格列奈类、α-葡萄糖苷酶抑制剂和其他类别。 2024 年，双胍类药物市场收入达 186 亿美元，其中二甲双胍作为最广泛使用的双胍类药物，继续保持其作为 2 型糖尿病一线治疗药物的主导地位。它透过降低肝臟葡萄糖生成和增加胰岛素敏感性来降低血糖水平的能力巩固了其在市场上的地位。此外，双胍类药物仍然是医疗保健提供者的首选，对市场稳定做出了重大贡献。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 459亿美元
预测值 666亿美元
复合年增长率 3.9%

从疾病类型来看，2024 年第 2 型糖尿病占据了主导地位，达到 95.6%。这与全球 2 型糖尿病盛行率的上升直接相关。城市化、不健康的饮食习惯和缺乏体能活动是导致第 2 型糖尿病早期发病的关键因素，尤其是在人口大国。因此，对方便、长期口服治疗方案的需求不断增长，加强了口服抗糖尿病药物在糖尿病管理中日益增长的作用。

在北美，口服抗糖尿病药物市场在 2024 年占有 41.1% 的份额。该地区糖尿病盛行率高，加上药物配方的不断进步和患者意识的提高，预计将继续推动市场成长。人口老化、久坐的生活方式以及不良的饮食习惯等因素导致该地区糖尿病发病率上升。此外，远距医疗和数位健康工具等医疗保健领域的创新使患者更容易管理自己的病情，进一步促进了口服抗糖尿病药物的采用。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

  • 产业生态系统分析
  • 产业衝击力
    • 成长动力
      • 2型糖尿病盛行率上升
      • 口服药物的偏好增加
      • 网路药局和电子商务的扩张
      • 联合疗法日益流行
    • 产业陷阱与挑战
      • 新型药物成本高昂
      • 副作用和安全问题
  • 成长潜力分析
  • 监管格局
  • 管道分析
  • 糖尿病概况
    • 2024 年全球各地区糖尿病患者数
    • 2024 年糖尿病患者数量最多的国家
    • 2024 年全球各地区糖尿病死亡人数
    • 预计 2045 年全球糖尿病患者数量最多的国家
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第四章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 策略仪表板

第五章：市场估计与预测：按药物类别，2021 - 2034 年

  • 主要趋势
  • 双胍类
  • 二肽基肽酶-4（DPP-4）抑制剂
    • 西他列汀
    • 利拉利汀
    • 维格列汀
    • 沙格列汀
    • 阿格列汀
    • 其他DPP-4抑制剂
  • 钠-葡萄糖转运蛋白-2（SGLT-2）抑制剂
    • 达格列净
    • 恩格列净
    • 卡格列净
  • 磺酰脲类药物
    • 格列美脲
    • 格列吡嗪
    • 格列苯脲
  • 噻唑烷二酮类
  • 格列奈类
    • 瑞格列奈
    • 那格列奈
  • α-葡萄糖苷酶抑制剂
  • 其他药物类别

第六章：市场估计与预测：依疾病类型，2021 - 2034 年

  • 主要趋势
  • 2型糖尿病
  • 1型糖尿病

第七章：市场估计与预测：按药物类型，2021 - 2034 年

  • 主要趋势
  • 品牌
  • 通用的

第八章：市场估计与预测：按配销通路，2021 - 2034 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第九章：市场估计与预测：按地区，2021 - 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第十章：公司简介

  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Merck
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Sanofi
  • Takeda Pharmaceuticals
简介目录
Product Code: 13377

The Global Oral Antidiabetic Drugs Market generated USD 45.9 billion in 2024 and is projected to expand at a CAGR of 3.9% from 2025 to 2034. The growth of this market is largely driven by the rising global prevalence of diabetes, particularly Type 2 diabetes (T2DM). The increasing number of people diagnosed with T2DM, especially in developing nations, can be traced back to the widespread adoption of sedentary lifestyles and poor dietary habits. Obesity, a major contributor to insulin resistance, has further intensified the demand for oral medications designed to regulate blood sugar levels. Medications such as sodium-glucose transport protein-2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors are becoming more popular. These drugs offer the added benefit of weight management in addition to effectively controlling blood glucose levels, giving patients a comprehensive solution to their condition.

Oral Antidiabetic Drugs Market - IMG1

This market is segmented by drug class into biguanides, SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas, thiazolidinediones, meglitinides, alpha-glucosidase inhibitors, and other categories. In 2024, the biguanides segment generated USD 18.6 billion, with Metformin, the most widely prescribed biguanide, maintaining its dominance as the first-line treatment for T2DM. Its ability to reduce blood glucose levels by lowering hepatic glucose production and increasing insulin sensitivity has solidified its position in the market. Furthermore, biguanides continue to be a primary choice for healthcare providers, contributing significantly to market stability.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$45.9 Billion
Forecast Value$66.6 Billion
CAGR3.9%

When considering disease type, the Type 2 diabetes segment accounted for a dominant 95.6% share in 2024. This is directly linked to the increasing prevalence of T2DM worldwide. Urbanization, unhealthy eating habits, and a lack of physical activity are key contributors to the early onset of T2DM, particularly in large-population countries. Consequently, there is a rising demand for convenient, long-term oral treatment options, reinforcing the growing role of oral antidiabetic drugs in managing diabetes.

In North America, the oral antidiabetic drugs market held a 41.1% share in 2024. The region's high prevalence of diabetes, combined with ongoing advancements in drug formulations and increased patient awareness, is expected to continue driving market growth. Factors such as aging populations, sedentary lifestyles, and poor dietary habits are contributing to the rising incidence of diabetes in the region. Additionally, innovations in healthcare, such as telemedicine and digital health tools, have made it easier for patients to manage their condition, further boosting the adoption of oral antidiabetic drugs.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of type 2 diabetes
      • 3.2.1.2 Increased preference for oral medications
      • 3.2.1.3 Expansion of online pharmacies and e-commerce
      • 3.2.1.4 Growing trend for combination therapies
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of newer drug classes
      • 3.2.2.2 Side effects and safety concerns
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Diabetes landscape
    • 3.6.1 Number of diabetics worldwide, by region, 2024
    • 3.6.2 Countries with the highest number of diabetics, 2024
    • 3.6.3 Number of diabetes deaths worldwide, by region, 2024
    • 3.6.4 Countries with the highest projected number of diabetics worldwide in 2045
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Biguanides
  • 5.3 Dipeptidyl peptidase - 4 (DPP-4) inhibitors
    • 5.3.1 Sitagliptin
    • 5.3.2 Linagliptin
    • 5.3.3 Vildagliptin
    • 5.3.4 Saxagliptin
    • 5.3.5 Alogliptin
    • 5.3.6 Other DPP-4 inhibitors
  • 5.4 Sodium-glucose transport protein-2 (SGLT-2) inhibitors
    • 5.4.1 Dapagliflozin
    • 5.4.2 Empagliflozin
    • 5.4.3 Canagliflozin
  • 5.5 Sulfonylureas
    • 5.5.1 Glimepiride
    • 5.5.2 Glipizide
    • 5.5.3 Glyburide
  • 5.6 Thiazolidinediones
  • 5.7 Meglitinides
    • 5.7.1 Repaglinide
    • 5.7.2 Nateglinide
  • 5.8 Alpha-glucosidase inhibitors
  • 5.9 Other drug classes

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Type 2 diabetes
  • 6.3 Type 1 diabetes

Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Branded
  • 7.3 Generic

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Astellas Pharma
  • 10.2 AstraZeneca
  • 10.3 Bayer
  • 10.4 Boehringer Ingelheim
  • 10.5 Bristol Myers Squibb
  • 10.6 Eli Lilly and Company
  • 10.7 Glenmark Pharmaceuticals
  • 10.8 Johnson & Johnson (Janssen Pharmaceuticals)
  • 10.9 Merck
  • 10.10 Novartis
  • 10.11 Novo Nordisk
  • 10.12 Pfizer
  • 10.13 Sanofi
  • 10.14 Takeda Pharmaceuticals